Neurological disorders such as epilepsy, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis present significant global health care challenges, …
Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.
To assess the efficacy of cannabis for the treatment of acute migraine. Preclinical and retrospective studies suggest cannabinoids may be effective in migrai…
Endocannabinoid System Research: Cannabinoids in Pediatrics
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence spanning interventional trials, observational studies, and patient surveys. The current body of research supports cautious clinical consideration...
Cannabinoids in Pediatric Care: Clinical Evidence Review
Clinical Takeaway Current evidence on cannabinoids in pediatric medicine spans 276 studies across multiple designs, with the strongest data coming from interventional and observational research on plant-derived and pharmaceutical cannabinoid treatments. The...
Cannabinoid Clinical Trials: Cannabis Effects on Alcohol Urge
Clinical Takeaway Cannabis does not affect alcohol urges the same way in everyone. People with lower working memory capacity may experience stronger alcohol cravings when using cannabis, while those with higher working...
Cannabinoid Clinical Trials: Cannabis Effects on Alcohol Urge
Clinical Takeaway Cannabis affects alcohol cravings differently depending on a person’s working memory capacity, meaning that cognitive factors help explain why some people experience increased or decreased urge to drink after using...
Cannabinoid Clinical Trials in Athlete Mental Health Care
Clinical Takeaway Retired professional athletes from high contact team sports show elevated rates of depression, anxiety, and cognitive concerns compared to the general population, with career-related head trauma and abrupt identity loss...
`Cannabinoid Clinical Trials: CBD and WADA Drug Testing`
Clinical Takeaway Daily use of a broad-spectrum CBD supplement containing trace amounts of other cannabinoids can result in urine concentrations of WADA-prohibited substances such as CBG and CBDV, potentially placing athletes at...
Cannabinoid Clinical Trials: Cannabis Effects on Alcohol Urge
Clinical Takeaway Cannabis can increase or decrease the urge to drink alcohol depending on a person’s working memory capacity, meaning the mental ability to hold and manage information. People with lower working...
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.